National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 25409-25410 [2023-08778]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 80 / Wednesday, April 26, 2023 / Notices
support public health activities for
refugees, immigrants and migrants that
are US-bound through the United States
Refugee Admission Program and in the
United States. Funding amounts for
years 2–5 will be set at continuation.
DATES: The period for this award will be
September 30, 2023, through September
29, 2028.
FOR FURTHER INFORMATION CONTACT:
Travis Myers, Division of Global
Migration and Quarantine, Immigrant,
Refugee, and Migrant Health Branch,
Centers for Disease Control and
Prevention, 1600 Clifton Rd. NE, MS
H16–4, Atlanta, GA 30329, Telephone:
770–530–6449, Email: QRK4@cdc.gov.
SUPPLEMENTARY INFORMATION: The
single-source award will establish
surveillance for infectious diseases in
new locations, evaluate the health status
of U.S. bound migrants for the purposes
of informing and improving U.S. policy
regarding overseas and post-arrival
health assessment with physicians and
prevent the importation and spread of
infectious disease into the United States
due to a global decrease in routine
immunization coverage and an increase
in vaccine-preventable diseases
outbreaks.
International Organization of
Migration is in a unique position to
conduct this work, as it carries out the
aims of the program due to its work
supporting screening activities of U.S.
bound populations with all US Panel
Physicians. IOM is an international and
intergovernmental organization that has
the technical and administrative
capacity to conduct health assessment
activities to support diseases.
ddrumheller on DSK120RN23PROD with NOTICES1
Summary of the Award
Recipient: International Organization
of Migration (IOM).
Purpose of the Award: The purpose of
this award is to support activities to
prevent and control efforts for infectious
diseases, including vaccine-preventable
disease, in U.S.-bound refugee
populations, as well as U.S.-bound
immigrant, non-immigrant visa (NIV)
applicants, parolees and other migrant
categories (from hereto called U.S.bound migrants) worldwide.
Amount of Award: $1,000,000 in
Federal Fiscal Year (FFY) 2023 funds,
subject to the availability of funds.
Funding amounts for years 2–5 will be
set at continuation.
Authority: This program is authorized
under the Public Health Service Act,
sections 307 and 317(k)(1) [42 U.S.C.
2421 and 247b(k)(1)].
Period of Performance: September 30,
2023, through September 29, 2028.
VerDate Sep<11>2014
19:28 Apr 25, 2023
Jkt 259001
Dated: April 21, 2023.
Terrance Perry,
Chief Grants Management Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2023–08790 Filed 4–25–23; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Award of a Single-Source
Cooperative Agreement To Fund
United Way of Middle Tennessee
Greater Nashville dba United Way of
Greater Nashville
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), located
within the Department of Health and
Human Services (HHS), announces the
award of approximately $4,000,000, for
one-year funding period to United Way
of Middle Tennessee dba United Way of
Greater Nashville. The award will fund
a community-based organization (CBO)
to expand the implementation of
comprehensive high-impact
community-based HIV prevention
programs in Tennessee.
DATES: The period for this award will be
June 1, 2023 through May 31, 2024.
FOR FURTHER INFORMATION CONTACT:
Erica K. Dunbar, National Center for
HIV, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention, 1600
Clifton Rd. NE, MS US8–3, Atlanta, GA
30329–4027, Telephone: 404–639–6048,
Email: CBOFOA@cdc.gov.
SUPPLEMENTARY INFORMATION: This
single-source award will: (1)
complement existing programs, such as
the Ryan White program and other HHS
programs, in the local jurisdictions; and
(2) address gaps in HIV prevention
services throughout the state of
Tennessee via direct funding of the
United Way of Middle TN dba United
Way of Greater Nashville (UWGN) and
indirect funding of CBOs throughout
Tennessee. Through this NOFO, a 1-year
cooperative agreement will be awarded
to ensure a continuity of services,
address gaps in services, and enhance
CBOs’ capacity to implement HIV
prevention strategies and activities.
United Way of Middle TN dba United
Way of Greater Nashville (UWGN)is in
a unique position to conduct this work,
as it has successfully served as the fiscal
SUMMARY:
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
25409
agent and program manager for the CDC
HIV prevention and Ending the HIV
Epidemic (EHE) programs funds
awarded to Tennessee. UWGN has a
proven track record of managing the
grants, as well as sub-grantee
relationships. Further, CBOs are
uniquely positioned to complement and
extend the reach of HIV prevention
efforts implemented by state and local
health departments. They support the
optimization of services across public,
private, and other community-based
organizations to achieve objectives of
increased identification of HIV
diagnoses, referral for pre-exposure
prophylaxis (PrEP) and nonoccupational post-exposure prophylaxis
(nPEP) services, earlier entry to HIV
care, and increased consistency of care.
Summary of the Awardee
Recipient: United Way of Middle
Tennessee dba United Way of Greater
Nashville (UWGN).
Purpose of the Award: The purpose of
this award is to enhance the capacity of
CBOs, through new and continued
funding relationships, to implement
integrated HIV programs, that
complement programs such as the Ryan
White program and other HHS
programs, within local health
department jurisdictions throughout the
State of Tennessee.
Amount of Award: $4,000,000 in
Federal Fiscal Year (FFY) 2023 funds,
with a total estimated $4,000,000 for the
one-year period of performance, subject
to availability of funds.
Authority: This program is authorized
under Sections 301 and 318(a) of the
Public Health Service Act; 42 U.S.C. 241
and 247c, as amended.
Period of Performance: June 1, 2023
through May 31, 2024.
Dated: April 21, 2023.
Terrance Perry,
Chief Grants Management Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2023–08791 Filed 4–25–23; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
E:\FR\FM\26APN1.SGM
26APN1
25410
Federal Register / Vol. 88, No. 80 / Wednesday, April 26, 2023 / Notices
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Implementation Cooperative Agreement (U01
Clinical Trial Required).
Date: May 19, 2023.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G58,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Anuja Mathew, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G58, Rockville, MD
20852, 301–761–6911, anuja.mathew@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: April 20, 2023.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–08748 Filed 4–25–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: April 20, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institutes of Health
[FR Doc. 2023–08778 Filed 4–25–23; 8:45 am]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
ddrumheller on DSK120RN23PROD with NOTICES1
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Ancillary Studies to
the IBD Genetics Consortium.
Date: June 20, 2023.
Time: 12:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute of Diabetes and Digestive
and Kidney Diseases, Democracy II, 6707
Democracy Blvd., Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Maria E. Davila-Bloom,
Ph.D., Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 7017, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7637, davila-bloomm@
extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
VerDate Sep<11>2014
19:28 Apr 25, 2023
Jkt 259001
National Institute on Aging; Notice of
Closed Meeting
Name of Committee: National Institute on
Aging Special Emphasis Panel; Clinical trials
for age-related conditions affecting mobility.
Date: June 6, 2023.
Time: 11:00 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Aging, Gateway
Building, 7201 Wisconsin Avenue, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Maurizio Grimaldi, M.D.,
Ph.D., Scientific Review Officer, National
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
Institute on Aging, National Institutes of
Health, 7201 Wisconsin Avenue, Room
2C218, Bethesda, MD 20892, 301–496–9374,
grimaldim2@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: April 20, 2023.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–08747 Filed 4–25–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01 Clinical
Trial Not Allowed).
Date: May 11, 2023.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G22,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Richard G. Kostriken,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G22,
Rockville, MD 20852, 240–669–2075,
richard.kostriken@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
E:\FR\FM\26APN1.SGM
26APN1
]]>Agencies
[Federal Register Volume 88, Number 80 (Wednesday, April 26, 2023)]
[Notices]
[Pages 25409-25410]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-08778]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
[[Page 25410]]
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID Clinical Trial Implementation
Cooperative Agreement (U01 Clinical Trial Required).
Date: May 19, 2023.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G58,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Anuja Mathew, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of Extramural Activities,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room 3G58, Rockville, MD
20852, 301-761-6911, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: April 20, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-08778 Filed 4-25-23; 8:45 am]
BILLING CODE 4140-01-P
